274 related articles for article (PubMed ID: 12184516)
1. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.
Graham DY
Dig Dis Sci; 2002 Aug; 47(8):1665-78. PubMed ID: 12184516
[TBL] [Abstract][Full Text] [Related]
2. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Lanza FL; Hunt RH; Thomson AB; Provenza JM; Blank MA
Gastroenterology; 2000 Sep; 119(3):631-8. PubMed ID: 10982755
[TBL] [Abstract][Full Text] [Related]
3. Role of alendronate and risedronate in preventing and treating osteoporosis.
Peters ML; Leonard M; Licata AA
Cleve Clin J Med; 2001 Nov; 68(11):945-51. PubMed ID: 11718433
[TBL] [Abstract][Full Text] [Related]
4. Comparative gastrointestinal safety of weekly oral bisphosphonates.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Levin R; Solomon DH
Osteoporos Int; 2009 Oct; 20(10):1735-47. PubMed ID: 19266138
[TBL] [Abstract][Full Text] [Related]
5. Safety considerations with bisphosphonates for the treatment of osteoporosis.
Strampel W; Emkey R; Civitelli R
Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
[TBL] [Abstract][Full Text] [Related]
6. 14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Thomson AB; Marshall JK; Hunt RH; Provenza JM; Lanza FL; Royer MG; Li Z; Blank MA;
J Rheumatol; 2002 Sep; 29(9):1965-74. PubMed ID: 12233894
[TBL] [Abstract][Full Text] [Related]
7. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
Baker DE
Rev Gastroenterol Disord; 2002; 2(1):20-33. PubMed ID: 12122976
[TBL] [Abstract][Full Text] [Related]
8. An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
Lanza F; Schwartz H; Sahba B; Malaty HM; Musliner T; Reyes R; Quan H; Graham DY
Am J Gastroenterol; 2000 Nov; 95(11):3112-7. PubMed ID: 11095326
[TBL] [Abstract][Full Text] [Related]
9. Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.
Lichtenberger LM; Romero JJ; Gibson GW; Blank MA
Dig Dis Sci; 2000 Sep; 45(9):1792-801. PubMed ID: 11052322
[TBL] [Abstract][Full Text] [Related]
10. Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
Peter CP; Handt LK; Smith SM
Dig Dis Sci; 1998 Sep; 43(9):1998-2002. PubMed ID: 9753265
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.
Peter CP; Kindt MV; Majka JA
Dig Dis Sci; 1998 May; 43(5):1009-15. PubMed ID: 9590415
[TBL] [Abstract][Full Text] [Related]
12. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Kherani RB; Papaioannou A; Adachi JD
Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
[TBL] [Abstract][Full Text] [Related]
13. Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.
Thomson AB; Appleman S; Keelan M; Wallace JL
Dig Dis Sci; 2003 Feb; 48(2):308-14. PubMed ID: 12643608
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical model for assessing gastric effects of bisphosphonates.
Blank MA; Ems BL; Gibson GW; Myers WR; Berman SK; Phipps RJ; Smith PN
Dig Dis Sci; 1997 Feb; 42(2):281-8. PubMed ID: 9052507
[TBL] [Abstract][Full Text] [Related]
16. [Esophageal lesions associated with diphosphonates].
Larsen KO; Stray N; Engh V; Sandnes D
Tidsskr Nor Laegeforen; 2000 Aug; 120(20):2397-9. PubMed ID: 11475224
[TBL] [Abstract][Full Text] [Related]
17. Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate.
Kanatsu K; Aihara E; Okayama M; Kato S; Takeuchi K
J Gastroenterol Hepatol; 2004 May; 19(5):512-20. PubMed ID: 15086594
[TBL] [Abstract][Full Text] [Related]
18. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonates. A cornerstone of osteoporosis treatment.
Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
[No Abstract] [Full Text] [Related]
20. [Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Kishimoto H
Clin Calcium; 2008 Oct; 18(10):1417-26. PubMed ID: 18830038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
